Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| ReCode Therapeutics | 2025 | Debt Financing | Undisclosed | Dallas |
| Neurogastrx | 2021 | Series B | Undisclosed | Woburn |
| GentiBio | 2021 | Series A | Undisclosed | Seattle |
| Belenos Biosciences | 2024 | Seed | Undisclosed | New York |
| Scorpion Therapeutics | 2024 | Series C | Undisclosed | Boston |
| Rhythm Pharmaceuticals | 2025 | Post-IPO Equity | Undisclosed | Boston |
| Renasant Bio | 2025 | Seed | Undisclosed | Berkeley |
| Upstream Bio | 2023 | Series B | Undisclosed | Waltham |
| Vigil Neuroscience | 2024 | Post-IPO Equity | Undisclosed | Cambridge |
| Nuvation Bio | 2026 | Post-IPO Debt | Undisclosed | New York |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 1 | ReCode Therapeutics | Debt Financing | Undisclosed | Dallas, United States |
| 2 | Neurogastrx | Series B | Undisclosed | Woburn, United States |
| 3 | GentiBio | Series A | Undisclosed | Seattle, United States |
| 4 | Belenos Biosciences | Seed | Undisclosed | New York, United States |
| 5 | Scorpion Therapeutics | Series C | Undisclosed | Boston, United States |
| 6 | Rhythm Pharmaceuticals | Post-IPO Equity | Undisclosed | Boston, United States |
| 7 | Renasant Bio | Seed | Undisclosed | Berkeley, United States |
| 8 | Upstream Bio | Series B | Undisclosed | Waltham, United States |
| 9 | Vigil Neuroscience | Post-IPO Equity | Undisclosed | Cambridge, United States |
| 10 | Nuvation Bio | Post-IPO Debt | Undisclosed | New York, United States |
ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics.
A private biopharmaceutical company .
GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.
Scorpion Therapeutics is a clinical-stage oncology company that specializes in precision medicine for cancer patients.
Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Upstream Bio focuses on developing an antibody therapy for the treatment of severe asthma.
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.
Helus Pharma is a biopharmaceutical company that develops psychedelic therapeutics for mental health conditions.
Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.
Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.
Ikena Oncology develops differentiated therapies to target cancer growth and resistance, focusing on Hippo and RAS signaling pathways.
Whitehawk Therapeutics, a clinical-stage oncology therapeutics firm, applies cutting-edge technologies to well-established tumor biology.
Forte Biosciences is a biotechnology company that focuses on dermatology.
Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.
vVardis develops oral care and dental treatment products using biomimetic peptide technology to address tooth decay and enamel repair.
Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.
Prelude Therapeutics designs and develops small molecule therapies targeting key drivers of cancer cell growth and resistance.
Nucleus RadioPharma is a new company built to ensure cancer patients can access potentially life-saving radiopharmaceuticals.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
OrbiMed has invested in 239 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
OrbiMed's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Pharmaceutical. The firm invests across 15 different industry categories.
Among tracked funding rounds, Triveni Bio received $115.0M in a Series C round. OrbiMed's total known invested capital is $12.2B.
OrbiMed's average investment size is $87.5M across its portfolio of 239 companies.
Recent OrbiMed portfolio additions include ReCode Therapeutics, Neurogastrx, GentiBio, Belenos Biosciences, Scorpion Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors